INVESTMENT CASE STUDY
Special Situation: A Post-Turnaround Equity Entry into Orchid Pharma
A post-resolution equity entry into Orchid Pharma, capturing the operational turnaround of a Chennai-based API manufacturer revived through India's IBC process.
At-a-Glance
The Opportunity
This investment was structured to hand our investors the reward of a corporate turnaround without its risk. Rather than betting on whether Orchid Pharma would survive insolvency, we waited until that question was already answered, the Supreme Court had cleared the resolution, a credible new promoter was in place, operations were stabilized, and regulatory approvals were reinstated. Investors stepped in only once the hardest part was over, buying into a pharma manufacturer with its plants running, its approvals intact, and its customer relationships preserved — capturing the recovery upside on a de-risked entry, not a speculative one.
Orchid Pharma, a Chennai-based manufacturer of active pharmaceutical ingredients and the only Indian pharma company to have discovered an approved New Chemical Entity, was identified by the Reserve Bank of India in August 2017 as one of 28 large corporate defaulters and referred into the Corporate Insolvency Resolution Process under the Insolvency and Bankruptcy Code. Despite the financial distress, the company's manufacturing plants continued operating through the process, preserving existing regulatory approvals and customer relationships that a liquidation and asset break-up would likely have disrupted.
Rationale
The default approach to a distressed-asset turnaround is to invest during the insolvency process itself, accepting judicial and process uncertainty in exchange for the deepest possible entry price. This entry took a different path: waiting until the Supreme Court had upheld the resolution plan and a stable, capitalized promoter was in place, before taking a position. This traded away the earliest, most uncertain entry point for a company with the insolvency and appellate risk already resolved, a going-concern operating base intact, and a committed promoter already funding the turnaround.
₹1,500 Cr
Total transaction size across both tranches
₹7,533.81
Floor price per share for the institutional tranche
₹300 Cr
Promoter warrant commitment, convertible within 18 months
27.22%
Standalone capital adequacy ratio (CRAR) ahead of the raise
Mechanics
The entry was structured as a secondary market equity purchase following the resolution plan's implementation, gaining exposure to the same capital structure the incoming promoter had already recapitalized.
Dual-Track Structure
An institutional QIP tranche was paired with a promoter warrant tranche to balance dilution against sponsor commitment.
QIB-Only Book
New shares priced near the floor were placed exclusively with qualified institutional buyers, including domestic mutual funds, insurers, and sovereign investors.
Warrant Conversion Window
Promoter warrants carry an 18-month exercise window rather than immediate conversion, spreading any future dilution over time.
Risk Factors: Managing the Downside
Track Record
For an entry structured around waiting out insolvency and appellate uncertainty before committing capital, the holding has tracked the company's post-resolution operating trajectory rather than the insolvency process itself. Orchid Pharma's plants have remained operational, and the company has continued under Dhanuka Laboratories' promotership with a restructured balance sheet.
This case study is shared for informational and illustrative purposes only. It describes a specific past transaction or structure and does not constitute investment advice, a recommendation, an offer, or a solicitation to invest in any security, scheme, or product. Cambridge Wealth (Baker Street Fintech Pvt. Ltd.) is a SEBI-registered Mutual Fund Distributor (ARN 172841) and does not provide investment advisory services; nothing in this document should be construed as personalized advice or a substitute for independent professional advice suited to your specific financial situation. This placement, where referenced, was made via Taksh India Enterprising Fund. Details of the underlying structure, terms, risks, and eligibility criteria are governed solely by that vehicle's private placement memorandum, offer document, or scheme information document, which should be read in full before making any investment decision. Figures, dates, and outcomes described are historical and specific to this transaction. Past performance, whether of this transaction, this asset class, or any comparable strategy, is not indicative of, and does not guarantee, future results. Any market or industry data cited is drawn from third-party or publicly available sources believed to be reliable but not independently verified by Cambridge Wealth, and is subject to change. No representation is made that any investor will or is likely to achieve outcomes similar to those described. Investments of the type described carry risk, including but not limited to market, credit, liquidity, currency, and regulatory risk, and may result in partial or total loss of capital. This document does not account for the objectives, financial situation, or needs of any specific investor. Prospective investors should independently assess suitability and consult their own legal, tax, and financial advisors before proceeding.